Allosteric regulation of PKM2 allows cellular adaptation to different physiological states

Science Signaling

Volumn 6, Issue 263, 2013, Pages

  Gui, Dan Y ^a   Lewis, Caroline A ^a   Vander Heiden, Matthew G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLOSUCCINATE LYASE; FRUCTOSE 1,6 BISPHOSPHATE; PHOSPHOTYROSINE; PYRUVATE KINASE; PYRUVATE KINASE M1; PYRUVATE KINASE M2; RIBOSE; SERINE; SUCCINYLAMINOIMIDAZOLECARBOXAMIDE RIBOSE 5' PHOSPHATE; UNCLASSIFIED DRUG;

ADAPTATION; ALLOSTERISM; BINDING SITE; BIOSYNTHESIS; CANCER CELL; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEEDBACK SYSTEM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; MACROMOLECULE; NEGATIVE FEEDBACK; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADAPTATION, PHYSIOLOGICAL; ALLOSTERIC REGULATION; CARRIER PROTEINS; HUMANS; MEMBRANE PROTEINS; THYROID HORMONES;

EID: 84874274833     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003925]     Document Type: Review

References (27)

1. R. A. Cairns, I. S. Harris, T. W. Mak, Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
2. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
3. B. Chaneton, P. Hillmann, L. Zheng, A. C. Martin, O. D. Maddocks, A. Chokkathukalam, J. E. Coyle, A. Jankevics, F. P. Holding, K. H. Vousden, C. Frezza, M. O'Reilly, E. Gottlieb, Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458-462 (2012).
4. K. E. Keller, I. S. Tan, Y. S. Lee, SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 338, 1069-1072 (2012).
5. H. R. Christofk, M. G. Vander Heiden, M. H. Harris, A. Ramanathan, R. E. Gerszten, R. Wei, M. D. Fleming, S. L. Schreiber, L. C. Cantley, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
6. L. Jiang, R. J. Deberardinis, Cancer metabolism: When more is less. Nature 489, 511-512 (2012).
7. S. Mazurek, Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969-980 (2011).
8. D. Anastasiou, Y. Yu, W. J. Israelsen, J. K. Jiang, M. B. Boxer, B. S. Hong, W. Tempel, S. Dimov, M. Shen, A. Jha, H. Yang, K. R. Mattaini, C. M. Metal-lo, B. P. Fiske, K. D. Courtney, S. Malstrom, T. M. Khan, C. Kung, A. P. Skoumbourdis, H. Veith, N. Southall, M. J. Walsh, K. R. Brimacombe, W. Leister, S. Y. Lunt, Z. R. Johnson, K. E. Yen, K. Kunii, S. M. Davidson, H. R. Christofk, C. P. Austin, J. In-glese, M. H. Harris, J. M. Asara, G. Stephanopou-los, F. G. Salituro, S. Jin, L. Dang, D. S. Auld, H. W. Park, L. C. Cantley, C. J. Thomas, M. G. Vander Heiden, Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847 (2012).
9. T. Noguchi, H. Inoue, T. Tanaka, The M1-and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 261, 13807-13812 (1986).
10. Y. Ikeda, T. Tanaka, T. Noguchi, Conversion of non-allosteric pyruvate kinase isozyme into an al-losteric enzyme by a single amino acid substitution. J. Biol. Chem. 272, 20495-20501 (1997).
11. T. Hitosugi, S. Kang, M. G. Vander Heiden, T. W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G. Z. Chen, J. Xie, T. L. Gu, R. D. Polakie-wicz, J. L. Roesel, T. J. Boggon, F. R. Khuri, D. G. Gilliland, L. C. Cantley, J. Kaufman, J. Chen, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2, ra73 (2009).
12. C. Kung, J. Hixon, S. Choe, K. Marks, S. Gross, E. Murphy, B. DeLaBarre, G. Cianchetta, S. Sethu-madhavan, X. Wang, S. Yan, Y. Gao, C. Fang, W. Wei, F. Jiang, S. Wang, K. Qian, J. Saunders, E. Driggers, H. K. Woo, K. Kunii, S. Murray, H. Yang, K. Yen, W. Liu, L. C. Cantley, M. G. Vander Heiden, S. M. Su, S. Jin, F. G. Salituro, L. Dang, Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19, 1187-1198 (2012).
13. H. R. Christofk, M. G. Vander Heiden, N. Wu, J. M. Asara, L. C. Cantley, Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186 (2008).
14. D. Anastasiou, G. Poulogiannis, J. M. Asara, M. B. Boxer, J. K. Jiang, M. Shen, G. Bellinger, A. T. Sasaki, J. W. Locasale, D. S. Auld, C. J. Thomas, M. G. Vander Heiden, L. C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283 (2011).
15. L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, Y. Xu, G. Wang, Y. Huang, Y. Xiong, K. L. Guan, Q. Y. Lei, Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730 (2011).
16. J. Ye, A. Mancuso, X. Tong, P. S. Ward, J. Fan, J. D. Rabinowitz, C. B. Thompson, Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 109, 6904-6909 (2012).
17. N. P. Manes, M. R. El-Maghrabi, The kinase activity of human brain 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase is regulated via inhibition by phosphoenolpyruvate. Arch. Biochem. Biophys. 438, 125-136 (2005).
18. M. G. Vander Heiden, J. W. Locasale, K. D. Swan-son, H. Sharfi, G. J. Heffron, D. Amador-Noguez, H. R. Christofk, G. Wagner, J. D. Rabinowitz, J. M. Asara, L. C. Cantley, Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499 (2010).
19. K. Ashizawa, P. McPhie, K. H. Lin, S. Y. Cheng, An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate. Biochemistry 30, 7105-7111 (1991).
20. R. Williams, T. Holyoak, G. McDonald, C. Gui, A. W. Fenton, Differentiating a ligand's chemical requirements for allosteric interactions from those for protein binding. Phenylalanine inhibition of pyruvate kinase. Biochemistry 45, 5421-5429 (2006).
21. K. Ashizawa, M. C. Willingham, C. M. Liang, S. Y. Cheng, In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1, 6-bisphosphate. J. Biol. Chem. 266, 16842-16846 (1991).
22. T. H. Murcott, H. Gutfreund, H. Muirhead, The cooperative binding of fructose-1, 6-bisphosphate to yeast pyruvate kinase. EMBO J. 11, 3811-3814 (1992).
23. J. D. Dombrauckas, B. D. Santarsiero, A. D. Mes-ecar, Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-9429 (2005).
24. Y. Ikeda, T. Noguchi, Allosteric regulation of py-ruvate kinase M2 isozyme involves a cysteine residue in the intersubunit contact. J. Biol. Chem. 273, 12227-12233 (1998).
25. A. Yacovan, R. Ozeri, T. Kehat, S. Mirilashvili, D. Sherman, A. Aizikovich, A. Shitrit, E. Ben-Zeev, N. Schutz, O. Bohana-Kashtan, A. Konson, V. Behar, O. M. Becker, 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specifi c M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 22, 6460-6468 (2012).
26. M. B. Boxer, J. K. Jiang, M. G. Vander Heiden, M. Shen, A. P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C. P. Austin, H. W. Park, J. Inglese, L. C. Cantley, D. S. Auld, C. J. Thomas, Evaluation of substituted N, N'-diarylsulfonamides as activators of the tumor cell specifi c M2 isoform of pyruvate kinase. J. Med. Chem. 53, 1048-1055 (2010).
27. E. Eigenbrodt, S. Leib, W. Kramer, R. R. Friis, W. Schoner, Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors. Biomed. Biochim. Acta 42, S278-S282 (1983).